Home » Stocks » HTBX

Heat Biologics, Inc. (HTBX)

Stock Price: $7.99 USD 0.08 (1.01%)
Updated Feb 26, 2021 1:36 PM EST - Market open
Market Cap 187.70M
Revenue (ttm) 4.34M
Net Income (ttm) -22.93M
Shares Out 20.53M
EPS (ttm) -1.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $7.99
Previous Close $7.91
Change ($) 0.08
Change (%) 1.01%
Day's Open 7.98
Day's Range 7.56 - 8.13
Day's Volume 524,387
52-Week Range 1.44 - 30.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Investors Business Daily - 2 weeks ago

Heat Biologics said Tuesday adding its experimental drug to Bristol Myers Squibb's Opdivo helped more lung-cancer patients survive. In response, HTBX stock catapulted.

InvestorPlace - 2 weeks ago

Heat Biologics (HTBX) stock is heating up on Tuesday after revealing interim data from a Phase 2 trial of its lung cancer treatment. The post Heat Biologics News: Why HTBX Stock Is Going Gangb...

Benzinga - 2 weeks ago

Heat Biologics Inc (NASDAQ: HTBX) soars in premarket on the heels of encouraging interim data from the Phase 2 trial evaluating HS-110, in combination with Bristol-Myers Squibb's (NYSE: BMY) O...

Seeking Alpha - 1 month ago

Heat Biologics: Investors Would Be Wise To Hold Off Until 2H 2021 Clinical Trial Interim Results

Accesswire - 1 month ago

DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate ...

Accesswire - 1 month ago

DURHAM, NC / ACCESSWIRE / January 11, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate ...

Accesswire - 1 month ago

DURHAM, NC / ACCESSWIRE / January 8, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate t...

Benzinga - 2 months ago

Esperion Therapeutics (NASDAQ: ESPR) shares are trading higher on Wednesday after the company announced Swiss Approval for the first-in-class cholesterol-lowering treatment NILEMDO and its Com...

Other stocks mentioned: ESPR, BLRX
InvestorPlace - 2 months ago

Heat Biologics (HTBX) has announced details for a reverse stock split in order to keep shares of HTBX stock trading on the Nasdaq. The post Heat Biologics Reverse Stock Split: 10 Things for HT...

Seeking Alpha - 3 months ago

Heat Biologics boosts patents portfolio with gp96 combination award. Teleflex announces acquisition of hemostatic company Z-Medica.

InvestorPlace - 5 months ago

Heat Biologics (HTBX) is in the news Thursday as HTBX stock takes a wild ride following an increasing focus on coronavirus stocks. The post Heat Biologics News: Why HTBX Stock Is On the Move T...

The Motley Fool - 5 months ago

COVID-19 vaccine stocks have gotten slammed this month.

Other stocks mentioned: AZN, BNTX, GSK, INO, JNJ, MRNA, NVAX, PFE, SNY, VXRT
The Motley Fool - 6 months ago

A pre-print is sending the biotech's shares higher today.

The Motley Fool - 6 months ago

Reports of an early approval for AstraZeneca's COVID-19 vaccine are sending these three stocks lower today.

Other stocks mentioned: INO, NVAX
The Motley Fool - 6 months ago

Encouraging early results for the biotech's coronavirus vaccine have investors excited.

The Motley Fool - 6 months ago

Russia's surprise vaccine announcement isn't sitting well with shareholders of Dynavax, Heat Biologics, or Inovio Pharmaceuticals.

Other stocks mentioned: DVAX, INO
The Motley Fool - 6 months ago

Heat Biologics and Vaxart could have a lot more room to run.

Other stocks mentioned: VXRT
The Motley Fool - 6 months ago

The biotech's COVID-19 vaccine candidate hit the mark in a preclinical study.

Benzinga - 8 months ago

Heat Biologics Inc (NASDAQ: HTBX) shares are trading higher on Monday after the company announced the first patient has been treated in its first-in-human clinical trial of PTX-35.

Forbes - 8 months ago

The market is powering through its third consecutive day of massive gains. Whether the market is too optimistic has been on the minds of many, considering how unstable the economy has been thi...

Other stocks mentioned: BAND, COF, EYPT, GHSI
Forbes - 8 months ago

As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks t...

Other stocks mentioned: BBI, DGLY, EYPT, MNKD

About HTBX

Heat Biologics, a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T... [Read more...]

Industry
Biotechnology
IPO Date
Jul 24, 2013
CEO
Jeffrey Wolf
Employees
36
Stock Exchange
NASDAQ
Ticker Symbol
HTBX
Full Company Profile

Financial Performance

In 2019, Heat Biologics's revenue was $3.05 million, a decrease of -47.37% compared to the previous year's $5.79 million. Losses were -$20.02 million, 27.2% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Heat Biologics stock is "Strong Buy." The 12-month stock price forecast is 29.25, which is an increase of 266.08% from the latest price.

Price Target
$29.25
(266.08% upside)
Analyst Consensus: Strong Buy